Search results
Results From The WOW.Com Content Network
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa).
The mammalian target of rapamycin (mTOR), [5] also referred to as the mechanistic target of rapamycin, and sometimes called FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a kinase that in humans is encoded by the MTOR gene. [6] [7] [8] mTOR is a member of the phosphatidylinositol 3-kinase-related kinase family of protein ...
mTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration. They function by inhibiting the mammalian target of rapamycin (mTOR) (also known as the mechanistic target of rapamycin), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases ...
Johnson had been taking rapamycin for five years and stopped last September. “I take this because there’s potentially some longevity benefits,” the 47-year-old explained in his documentary.
Rapamycin is a macrolide which is an immunosuppressant in humans that inhibits mTOR by binding to its intracellular receptor FKBP12. In many cancers, hyperactive AKT signaling leads to increased mTOR signaling, so rapamycin has been considered as an anti-cancer therapeutic for cancers with PTEN inactivation. Numerous clinical trials involving ...
Target of rapamycin complex subunit LST8, also known as mammalian lethal with SEC13 protein 8 (mLST8) or TORC subunit LST8 or G protein beta subunit-like (GβL or Gable), is a protein that in humans is encoded by the MLST8 (MTOR associated protein, LST8 homolog) gene. [5]
Sirolimus (also known as rapamycin) is an antifungal and immunosuppressant that has been isolated from S. hygroscopicus from soil samples from Easter Island. [4] Ascomycin is another immunosuppressant produced by some strains of S. hygroscopicus; it has a similar structure to sirolimus and can be used to treat autoimmune diseases and skin diseases and can help prevent rejection after an organ ...
Loyal raised $125 million in funding from investors – originally, it was going to focus on human longevity, but changed strategy due to the decades-long testing needed to work on humans.